@PaulSaxMD
Paul Sax
3 years
With nirmatrelvir (Paxlovid) and molnupiravir not yet available, and the most widely used MAbs lacking activity against Omicron (+ other issues), is it time to bump up fluvoxamine at least to "consider use" status on the treatment guidelines? Two well-done RCTs show benefit.
@boulware_dr
David Boulware, MD MPH
3 years
Tweet media one
34
280
649
23
131
451

Replies

@ASPphysician
Andrew Morris
3 years
@PaulSaxMD We will be making this very recommendation in Ontario very shortly. @COVIDSciOntario @MPaiMD
1
4
49
@PaulSaxMD
Paul Sax
3 years
@ASPphysician @COVIDSciOntario @MPaiMD Very interesting! Hope we do the same in the USA.
1
1
8
@lukesophinos
Luke Sophinos
3 years
@PaulSaxMD This is good to know, thank you.
0
0
0
@ZimermanRicardo
Dr. Ricardo Zimerman
3 years
@PaulSaxMD Actually one of the first SSRI..,
0
0
3
@StephenJack4
Jack
3 years
@PaulSaxMD Yes, it would seem to be a good bridging strategy till Paxlovid and Sotrimivab becomes available at scale.
1
1
5
@eeeejjjaaaa
1+
3 years
@PaulSaxMD I really think so… can still refer pt to mab infusion but while waiting (anticipate there might be shortage of sotrov soon for obvious reason?)
0
1
4
@DrToddLee
Todd C. Lee
3 years
@PaulSaxMD Yes. I'd look at fluvoxamine, inhaled steroids or colchicine in that order and depending on patient factors like drug interactions and comorbidities
2
1
17
@Cleo_4a
Cleo4
3 years
@PaulSaxMD Fluvoxamine seems at least as effective as molnupiravir and with fewer potential side effects. And of course, available now.
0
1
4
@jlamfer
jlamfer
3 years
@PaulSaxMD Why not inhaled budesonide??
1
0
0
@KyleBumpus
Kyle Bumpus
3 years
@PaulSaxMD Does the FDA even have this on the docket?
1
0
0
@LCalabreseDO
Leonard Calabrese
3 years
@PaulSaxMD YES - NOW - and people may be able to get it and have it on a shelf without declaring bankruptcy
0
0
1
@DavidAlainWohl
David Alain Wohl
3 years
@PaulSaxMD NIH guideline recs & summary on fluvoxamine and inhaled steroids certainly no ringing endorsement and points out important limitations of the studies:
0
1
4
@paulsummergrad
Paul Summergrad
3 years
@PaulSaxMD While the effects where modest both trials - showed benefit although with some less than key endpoints. The downside risk is low and there is not an interaction with ritonavir if that becomes available in the paxlovid regimen.
0
1
1
@ttmrsuch3
Thomas Jr. R.Ph.
3 years
@PaulSaxMD Fluvoxamine belonging to the class of SSRI’s is a potent CYP 3A4 inhibitor, which can cause an increase in the levels of many other meds not to mention QT prolongation. Also has a black box warning for risk of suicide in adolescents. Would have to use extreme caution .
3
1
2
@DrMJoyner
Michael Joyner
2 years
@PaulSaxMD @pash22 More recent RCTs confirm that high titer CP given early works, Hybrid plasma from those who have been infected & vaxed covers variants. There will more data early this week.
0
0
2
@AaronRichterman
Aaron Richterman, MD
2 years
@PaulSaxMD Yes, and redirect infusion center efforts from mabs to remdesivir based on PINETREE?
1
0
4
@TheBingle
Bingle
2 years
@PaulSaxMD Tell me why doctors didn't tell HTLV-III/AIDS patients alcohol in a small amount can keep you alive? Instead, it was said nothing on shelves worked.
0
0
0
@vinodsethMD
Vinod K Seth MD, Prof Clinical Medicine (Retd)
2 years
@PaulSaxMD Available in India and with the unavoidable surge from Omicron soon consider having on hand for those with underlying disease. Screenshot of the TOGETHER trial website page with dealing with results of Fluvoxamine in early COVID-19.
Tweet media one
0
0
2